{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:40:38Z","timestamp":1778751638983,"version":"3.51.4"},"reference-count":25,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,3,23]],"date-time":"2005-03-23T00:00:00Z","timestamp":1111536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p>\n                    <jats:bold>Background:\u2002<\/jats:bold>\n                    Early weight loss is generally considered to predict long\u2010term weight outcome in obese patients, and this is reflected in prescribing guidelines for antiobesity drugs. For example, the current prescribing guidelines for the antiobesity drug, sibutramine, indicate that if patients have not lost 2\u2003kg (or 4\u2003lb) in the first 4\u2003weeks of treatment with sibutramine 10\u2003mg, the physician should re\u2010evaluate the therapy, which may result in increasing the dose to 15\u2003mg or discontinuation. This regimen may deny treatment to a large group of patients who might otherwise benefit, particularly patients with type 2 diabetes who often find it more difficult to lose weight than non\u2010diabetic obese individuals.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Materials:\u2002<\/jats:bold>\n                    We have re\u2010analysed pooled data from seven randomized, controlled studies of sibutramine\u2010induced weight loss and maintenance in which patients (n\u2003=\u2003928; 75% female) had taken sibutramine 10 or 15\u2003mg continuously for 12\u2003months, in order to determine the predictors of success in weight loss (defined as loss of at least 5% of initial body weight at Month 12) in both diabetic and non\u2010diabetic patients. Sensitivity and specificity analyses were used to calculate optimal predictive values.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    In both diabetic and non\u2010diabetic patients, weight loss of 4\u2003kg at 3\u2003months was identified as the optimal predictor for achieving at least 5% weight loss at 12\u2003months. This target was associated with the best average values for sensitivity, specificity and accuracy, as well as high positive (78% vs. 84% for non\u2010diabetics and 76% vs. 85% for diabetics, compared to existing guidelines target of 2\u2003kg after 1\u2003month treatment) and negative predictive values (63% vs. 71% for non\u2010diabetics; 52% vs. 70% for diabetics).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:\u2002<\/jats:bold>\n                    Sibutramine, in conjunction with diet and exercise, should be continued for at least 3\u2003months (providing there are no adverse effects) to determine whether or not patients are likely to achieve a clinically valid outcome at 1\u2003year. This highlights the need to ensure that regulatory restrictions reflect the needs of clinical practice.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2005.00481.x","type":"journal-article","created":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T05:03:01Z","timestamp":1138770181000},"page":"206-213","source":"Crossref","is-referenced-by-count":52,"title":["Prediction of response to sibutramine therapy in obese non\u2010diabetic and diabetic patients"],"prefix":"10.1111","volume":"8","author":[{"given":"N.","family":"Finer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. H.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. L.","family":"Renz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"Hewkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,3,23]]},"reference":[{"key":"e_1_2_5_2_2","volume-title":"Obesity: Preventing and Managing the Global Epidemic.","author":"World Health Organization.","year":"2000"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370100063012"},{"key":"e_1_2_5_4_2","first-page":"688","article-title":"Treatment of obesity by moderate and severe calorie restriction: results of clinical research trials","volume":"119","author":"Wadden TA","year":"1993","journal-title":"Arch Intern Med"},{"key":"e_1_2_5_5_2","first-page":"123","article-title":"Long\u2010term follow\u2010up of behavioral treatment for obesity: patterns of weight regain among men and women","volume":"13","author":"Kramer FM","year":"1989","journal-title":"Int J Obes Relat Metab Disord"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.1999.10718897"},{"key":"e_1_2_5_7_2","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1001\/jama.1996.03540230057036","article-title":"Long\u2010term pharmacotherapy in the management of obesity","volume":"276","author":"National Task Force on the Prevention and Treatment of Obesity.","year":"1996","journal-title":"JAMA"},{"key":"e_1_2_5_8_2","volume-title":"Anti\u2010Obesity Drugs: Guidance on Appropriate Prescribing and Management.","author":"Royal College of Physicians of London.","year":"2003"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1999.tb00701.x"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00411-2"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000047310"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2000.00071.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.1.125"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801481"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1467-789x.2000.00004.x"},{"key":"e_1_2_5_16_2","unstructured":"US Prescribing Information. Abbott Laboratories."},{"key":"e_1_2_5_17_2","unstructured":"European Prescribing Information. Abbott Laboratories."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.10.5.563"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802591"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-817934"},{"key":"e_1_2_5_21_2","unstructured":"Australian Prescribing Information. Abbott Laboratories."},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03491-7"},{"key":"e_1_2_5_23_2","first-page":"505","article-title":"Randomized placebo\u2010controlled trial of long\u2010term treatment with sibutramine in mild to moderate obesity","volume":"50","author":"Smith IG","year":"2001","journal-title":"J Fam Pract"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.11.1331"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/78.2.209"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200308000-00003"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2005.00481.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2005.00481.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:20:58Z","timestamp":1761884458000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2005.00481.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,23]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1463-1326.2005.00481.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2005.00481.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,3,23]]}}}